Effect of baseline VEGF-D concentrations on selected clinical measurements during the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial
A general linear model (adjusted for baseline concentration, age, and height) was the basis for calculation of p values for mean 12 month differences in lung function and patient-reported outcomes between the placebo and sirolimus groups depending on baseline log(VEGF-D). A mixed-effects linear model (adjusted for age and height) was used to calculate per month p values for no slope difference between the placebo and sirolimus groups depending on baseline log(VEGF-D). Data are parameter estimates for log(VEGF-D) and associated SE from the general linear and the linear mixed effects models. Functional performance inventory is scored from 1 to 4, the general wellbeing questionnaire from 0 to 110, and the European quality of life visual analogue scale from 0 to 100; low score suggests poor health status. St George's respiratory questionnaire is scored from 0 to 100; low score suggests good health status.
* p for no effect of log(VEGF-D) of less than 0·01.